94 related articles for article (PubMed ID: 3870537)
1. [Prolactin and cancer of the breast. II. Prediction of the response to hormone treatment. The Minton test].
Cueto Ladrón de Guevara J; García Puche JL; Pedraza V
Rev Esp Oncol; 1985; 32(3):459-70. PubMed ID: 3870537
[TBL] [Abstract][Full Text] [Related]
2. [Breast cancer and hormone therapy].
Izuo M
Gan To Kagaku Ryoho; 1987 Oct; 14(10):2830-6. PubMed ID: 2959203
[TBL] [Abstract][Full Text] [Related]
3. Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.
Nesković-Konstantinović ZB; Nikolić-Vukosavljević DB; Branković-Magić MV; Mitrovic LB; Spuzić I
Neoplasma; 2000; 47(2):107-13. PubMed ID: 10985476
[TBL] [Abstract][Full Text] [Related]
4. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
[TBL] [Abstract][Full Text] [Related]
5. Effect of bicalutamide therapy on prolactin response to L-dopa in metastatic prostate cancer patients.
Lissoni P; Malugani F; Casu M; Bukovec R; Egardi R; Bordin V; Fumagalli E; Mengo S; Gardani G
Neuro Endocrinol Lett; 2002 Feb; 23(1):61-3. PubMed ID: 11880864
[TBL] [Abstract][Full Text] [Related]
6. Effect of prednisolone on hormone profiles during primary endocrine treatment of advanced breast cancer.
Blackburn AM; Wang DY; Bulbrook RD; Thomas BS; Kwa HG; Hoare SA; Rubens RD
Cancer Treat Rep; 1984 Dec; 68(12):1447-53. PubMed ID: 6239689
[TBL] [Abstract][Full Text] [Related]
7. Can plasma prolactin predict tamoxifen resistance in patients with advanced breast cancer?
Bhatavdekar JM; Patel DD; Karelia NH; Shah NG; Ghosh N; Vora HH; Suthar TP; Balar DB; Doctor SS
Eur J Surg Oncol; 1994 Apr; 20(2):118-21. PubMed ID: 8181575
[TBL] [Abstract][Full Text] [Related]
8. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma.
Nola M; Jukić S; Ilić-Forko J; Babić D; Uzarević B; Petrovecki M; Suchanek E; Skrablin S; Dotlić S; Marusić M
Gynecol Oncol; 1999 Mar; 72(3):331-6. PubMed ID: 10053103
[TBL] [Abstract][Full Text] [Related]
9. [Hormone treatment of metastasizing breast carcinoma].
Navarra S; Melita P; Di Mauro S; Calbo L; Belnome N
Minerva Chir; 1981 Jun; 36(12):853-60. PubMed ID: 6454856
[TBL] [Abstract][Full Text] [Related]
10. Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial.
Nicolini A; Carpi A
Biomed Pharmacother; 2005 Jun; 59(5):253-63. PubMed ID: 15913946
[TBL] [Abstract][Full Text] [Related]
11. Plasma prolactin concentrations and risk of postmenopausal breast cancer.
Tworoger SS; Eliassen AH; Rosner B; Sluss P; Hankinson SE
Cancer Res; 2004 Sep; 64(18):6814-9. PubMed ID: 15375001
[TBL] [Abstract][Full Text] [Related]
12. Antiestrogen treatment of breast cancer: an overview.
Pearson OH; Manni A; Arafah BM
Cancer Res; 1982 Aug; 42(8 Suppl):3424s-3429s. PubMed ID: 7044524
[TBL] [Abstract][Full Text] [Related]
13. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients.
Mandalà M; Moro C; Ferretti G; Calabro MG; Nolè F; Rocca A; Munzone E; Castro A; Curigliano G
Anticancer Res; 2001; 21(1B):585-8. PubMed ID: 11299809
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory action on GHRH-induced GH secretion of chronic tamoxifen treatment in breast cancer.
De Marinis L; Mancini A; Izzi D; Bianchi A; Giampietro A; Fusco A; Liberale I; Rossi S; Valle D
Clin Endocrinol (Oxf); 2000 Jun; 52(6):681-5. PubMed ID: 10848871
[TBL] [Abstract][Full Text] [Related]
15. [Adjuvant endocrine forms of therapy in breast cancer].
Jakesz R; Hausmaninger H
Wien Klin Wochenschr; 1984 Jun; 96(13):492-9. PubMed ID: 6475078
[TBL] [Abstract][Full Text] [Related]
16. [Hormone therapy in breast cancer].
Rouëssé J
Chirurgie; 1994-1995; 120(6-7):330-7. PubMed ID: 7768120
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant hormonal therapy for premenopausal women with breast cancer.
Brown RJ; Davidson NE
Semin Oncol; 2006 Dec; 33(6):657-63. PubMed ID: 17145345
[TBL] [Abstract][Full Text] [Related]
18. Expression of prolactin receptor mRNA in oestrogen receptor positive breast cancers pre- and post-tamoxifen therapy.
de Castillo B; Cawthorn S; Moppett J; Shere M; Norman M
Eur J Surg Oncol; 2004 Jun; 30(5):515-9. PubMed ID: 15135479
[TBL] [Abstract][Full Text] [Related]
19. [Developments in endocrine therapy for breast cancer].
Matsui A; Ikeda T; Jinno H; Tajima G; Hohjou T; Tokura H; Mitsui Y; Asaga S; Muto T; Kitajima M
Gan To Kagaku Ryoho; 2002 Jul; 29(7):1138-45. PubMed ID: 12145993
[TBL] [Abstract][Full Text] [Related]
20. Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients.
Kirkegaard T; McGlynn LM; Campbell FM; Müller S; Tovey SM; Dunne B; Nielsen KV; Cooke TG; Bartlett JM
Clin Cancer Res; 2007 Mar; 13(5):1405-11. PubMed ID: 17332282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
